Pacira Drug Promotion Suit Settled With Broad Concessions From FDA
This article was originally published in The Gray Sheet
The agency will formally rescind Exparel warning letter and expand labeling to clarify that pain drug is not limited to any specific surgery. The drug case has been closely watched for implications on FDA's oversight of off-label communications for both drugs and devices.
Register for our free email digests: